1-4 of 4
Nancy Pryer
Close
Sort by
Journal Articles

Impact of Pre-Existing Immunogenicity to AAV on Vector Transduction By Bmn 270, an AAV5-Based Gene Therapy Treatment for Hemophilia A

Brian Long, PhD MS, BSMedTech, Krystal Sandza, Jennifer Holcomb, Juli Pherarolis, Lucy Crockett, Lillian Falese, Greg Hayes, Jeremy Arens, Charles A. O'Neill, Nancy Pryer, Carlos Fonck, Stephen Zoog, Christian Vettermann
Journal: Blood
Blood (2017) 130 (Supplement 1): 3332.
https://doi.org/10.1182/blood.V130.Suppl_1.3332.3332
Published: 2017
Journal Articles

Interim Analysis of Immunogenicity to the Vector Capsid and Transgene-Expressed Human FVIII in a Phase-1/2 Clinical Study of Bmn 270, an AAV5-Mediated Gene Therapy for Hemophilia a

Brian Long, PhD MS, BSMedTech, Benjamin Kim, Wing Yen Wong, Ke Yang, Christian Vettermann, Nancy Pryer, Romain Hardet, Klaudia Kuranda, Philippe Veron, Federico Mingozzi, Glenn F. Pierce, Becky Schweighardt
Journal: Blood
Blood (2017) 130 (Supplement 1): 4611.
https://doi.org/10.1182/blood.V130.Suppl_1.4611.4611
Published: 2017
Journal Articles

Efficacy of an Antagonistic Anti-CD40 Monoclonal Antibody, HCD122 (CHIR-12.12), in Preclinical Models of Human Non-Hodgkin’s Lymphoma and Hodgkin’s Disease.

Li Long, PhD, Montesa Patawaran, B.Sc., Xia Tong, M.Sc., Seema Kantak, Ph.D., Sharon L. Aukerman, Ph.D., Nancy Pryer, Ph.D., Mohammad Luqman, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 230.
https://doi.org/10.1182/blood.V108.11.230.230
Published: 2006
Journal Articles

CHIR-258 Efficacy in a Newly Developed Preclinical Bone Marrow Model of t(4;14) Multiple Myeloma.

Xiaohua Xin, PhD, Yan Tang, MD, Yoko Oei, BA, Helen Ye, BS, Daniel Menezes, PhD, Katherine Rendahl, PhD, Paul Hollenbach, MS, Nancy Pryer, PhD, Suzanne Trudel, MD, Dirk Mendel, PhD, Bahija Jallal, PhD, Carla Heise, PhD
Journal: Blood
Blood (2005) 106 (11): 3449.
https://doi.org/10.1182/blood.V106.11.3449.3449
Published: 2005